Sernova Biotherapeutics Inc
PSH0
Company Profile
Business description
Sernova Biotherapeutics Inc is a clinical-stage company developing regenerative medicines. The company develops Cell Pouch with human donor cells or stem cells to create a biohybrid organ. The Cell Pouch is a implantable medical device designed to create a vascularized organ-like environment for the transplantation and engraftment of therapeutic cells, which then release proteins, hormones, or other factors into the bloodstream for the long-term treatment of multiple chronic diseases such as type 1 diabetes, hypothyroid disease, and rare diseases such as hemophilia A.
Contact
700 Collip Circle
Suite 114
LondonONN6G 4X8
CANT: +1 877 299-4603
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 October 2026
Employees
17
Stocks News & Analysis
stocks
2 ASX shares that benefit from sticky inflation
Inflation is a key risk to shareholders. Here’s why these two ASX shares benefit from higher inflation.
stocks
Undervalued ASX retailer benefiting from rebound in spending
Uplift in sales momentum continues.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,923.80 | 7.50 | -0.08% |
| CAC 40 | 8,156.89 | 88.27 | 1.09% |
| DAX 40 | 24,306.65 | 120.16 | 0.50% |
| Dow JONES (US) | 48,458.05 | 245.96 | -0.51% |
| FTSE 100 | 9,736.96 | 87.93 | 0.91% |
| HKSE | 25,628.88 | 347.91 | -1.34% |
| NASDAQ | 23,195.17 | 398.69 | -1.69% |
| Nikkei 225 | 50,168.11 | 668.44 | -1.31% |
| NZX 50 Index | 13,408.14 | 1.23 | 0.01% |
| S&P 500 | 6,827.41 | 73.59 | -1.07% |
| S&P/ASX 200 | 8,635.00 | 8.90 | -0.10% |
| SSE Composite Index | 3,867.92 | 21.42 | -0.55% |